ServiceNow Releases Four Apps to Help Companies Handle Essential Steps to Returning Employees Safely to the Workplace
ServiceNow (NYSE: NOW), the leading digital workflow company that makes work, work better for people, today released ServiceNow Safe Workplace, a four-app suite and dashboard designed to help companies manage the essential steps for returning employees to the workplace and support everyone’s health and safety. Immediately available on servicenow.com/safeworkplace, the Safe Workplace app suite is powered by the Now Platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005797/en/
ServiceNow Safe Workplace Apps and Dashboard (Graphic: Business Wire)
“Let’s get the world healthy, safe and back to the workplace,” said Bill McDermott, ServiceNow CEO. “ServiceNow is helping companies manage the complex workflows required to keep employees healthy and workplaces safe. The ServiceNow Safe Workplace app suite and dashboard are engineered to make returning to the workplace work for everyone.”
ServiceNow Safe Workplace Apps and Dashboard
ServiceNow has expanded its employee workflow portfolio with the ServiceNow Safe Workplace app suite. Powered by the Now Platform, the suite includes four new apps and a dashboard that help companies assess both their workforce and workplace readiness as they prepare for employees to return to the workplace.
“In the wake of the COVID-19 pandemic, business transformation is happening before our eyes and organizations are relying on technology to enable employees and digitize processes,” said Josh Bersin, Global Industry Analyst and Dean of the Josh Bersin Academy. “ServiceNow’s Safe Workplace app suite is exactly the kind of solution organizations need to effectively manage the return to the workplace and optimize employee experience.”
To support companies’ workforce readiness efforts led by Human Resources, IT, Legal and Workplace Services departments, ServiceNow has released the following apps:
- Employee Readiness Surveys: Helps organizations gauge their workforce’s level of preparedness to return to the workplace by presenting and capturing employee responses to a series of questions that address employees’ personal readiness for and level of interest in returning to the workplace. Based on employee responses, employers can determine the necessary and appropriate steps to help ensure a smooth and safe re-entry for employees.
- Employee Health Screening: Enables companies to screen employees before entering the workplace to ensure compliance with entry requirements such as temperature check and personal protective equipment (PPE) allowing employers to determine if it’s safe for the employee to enter the workplace. The app also provides a reporting dashboard to view trends by sites and record the return of employees into their facilities.
ServiceNow also released two new apps to support companies’ preparedness to bring employees back to the workplace:
- Workplace Safety Management: Allows facilities and workplace services managers to quickly configure clean and hygienic, socially distanced workspaces so that employees can safely return to the workplace. The app lets managers assign shifts so that employees occupy these workspaces for a specific amount of time and configure cleaning schedules at the end of each shift. Out-of-the-box reports and dashboards give managers a real-time view of both workspace reservations and reservation thresholds across floors, buildings and sites. Workplace managers also have a real-time view of all cleaning task status, including a full audit trail history.
- Workplace PPE Inventory Management: Helps organizations manage and monitor their PPE inventory needs to ensure the physical safety of their workforce. The app’s dashboard provides a comprehensive view of inventory by facility, as well as an aggregate look at the entire workplace and historical data on how equipment levels have changed over time. Inventory levels can be updated daily for accurate, real-time inventory management.
Using the power of the Now Platform, ServiceNow pulls together all of the data collected by these apps into a single view with its Safe Workplace Dashboard. Available at no charge, the dashboard provides visualizations for data collected by these apps, and will be overlaid with a map using aggregated public data on infection rates. This enables organizations to see what infections look like geographically and drill down into specific workplace locations. Sites are marked with indicators flagging a company’s ability to open and remain open based on workforce and workplace readiness.
“At Lincoln we have teams across the organization working tirelessly to develop, communicate and execute a plan for returning our employees to the workplace,” said Lisa M. Buckingham, executive vice president and chief people, place and brand officer for Lincoln Financial Group. “There is no margin for error when it comes to the health and safety of our employees and given the constantly changing circumstances and multitude of factors at play, technology solutions like those offered by ServiceNow are invaluable in effectively coordinating, monitoring and evaluating our plans and progress.”
Returning employees to the workplace requires careful planning, execution and agility on the part of organizations. Business functions across the enterprise – from IT and HR to Workplace Services and Legal – must work together seamlessly to create a safe and productive experience for all employees, whether they return to the workplace or continue to work from home. These are workflow problems. Complex, cross-functional workflows are critical to providing employees the services and experiences needed to do their jobs seamlessly and efficiently, no matter where they are.
ServiceNow’s comprehensive employee workflow products enable these and other experiences to happen simply and easily. For example, ServiceNow’s existing Targeted Campaigns capabilities can inform different groups of employees – such as employees located in specific geographies or in certain departments – of return to workplace plans, engage employees for feedback and initiate workflows to act on that feedback. Additionally, ServiceNow’s Lifecycle Event Engine can create workflows associated with the employee’s journey – like returning to the workplace, onboarding, transfers and leave of absences. Lifecycle Event’s capabilities can be used to automate processes spanning HR, IT, Workplace Services and other functions to support returning employees to the workplace seamlessly.
Organizations that are digitally transformed with digital workflows in place will be better-enabled to get back to work more efficiently, productively and safely. ServiceNow is committed to helping its customers manage through this pandemic and make going back to the workplace work for everyone.
Expanding on Emergency Response Apps
Today’s announcement builds upon ServiceNow’s March 16th introduction of a customer care program to support customers as they focus on maintaining business operations during the COVID‑19 pandemic. As part of the March announcement, the company released four community apps that help government agencies and enterprises manage complex emergency response workflows. These apps are available at servicenow.com/crisisresponse for customers to access free of charge through September 30, 2020. Almost 6,000 installations have taken place to date.
Today ServiceNow also released updates to two of these apps to further support companies as they pivot to return their workforce to a traditional workplace. These updates include:
- Emergency Self Report: This app helps an employee notify their employer that they are self-quarantined and when the employee will return to the workplace, and provides workflow support for the employer. The app is now supported on Now Mobile so that employees can self report from their desktop or mobile device.
- Emergency Outreach: This app helps companies connect with employees to assess the impact. Employers can reach out by email to provide information and safety measures and request a response to confirm if employees are safe and where they are located. Employers can also leverage the ServiceNow Now Mobile App to send push notifications to employees via mobile to get response. ServiceNow has updated Emergency Outreach to integrate with other communications channels such as Slack and Microsoft Teams.
Across ServiceNow’s global community, we recognize that so many are in need of support as a result of COVID-19. ServiceNow and its employees stepped up over the last few months with a $1.5M commitment. Corporate grants included the American Red Cross, CDC Foundation, International Medical Corps, Mayor’s Fund to Advance New York City, Second Harvest of Silicon Valley, Silicon Valley Community Foundation and the United Nations Foundation. These funds will help address a number of relief efforts related to COVID-19, including providing training, meals and personal protective equipment for front-line medical staff and other essential workers, food and housing support for needy families and individuals, grants and low-interest loans for small businesses and more.
ServiceNow (NYSE: NOW) is making the world of work, work better for people. Our cloud‑based platform and solutions deliver digital workflows that create great experiences and unlock productivity for employees and the enterprise. For more information, visit: www.servicenow.com.
© 2020 ServiceNow, Inc. All rights reserved. ServiceNow, the ServiceNow logo, Now, and other ServiceNow marks are trademarks and/or registered trademarks of ServiceNow, Inc. in the United States and/or other countries. Other company names, product names, and logos may be trademarks of the respective companies with which they are associated.
For more information:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EEST | Press release
Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r
Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke
LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EEST | Press release
LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom